Product logins

Find logins to all Clarivate products below.


Going Global? What Can You Expect for Device Pricing?

The United States accounts for the single largest proportion of the global medical device market, representing approximately 40% of the estimated $400 billion (USD) global market in 2014. Its large affluent population, tendency to adopt innovative technologies, and high device average sales prices (ASPs); it thus remains the single most attractive market for device manufacturers. However, the United States is not immune to the concerns of the rising cost of healthcare, and device manufacturers that have not already done so would be wise to diversify beyond the United States . However, expansion beyond its borders brings with it a whole host of challenges that manufacturers will need to understand in order to succeed.

Even with a safe and efficacious device and strong demand from the physician community, commercializing a device in a non-U.S. country can be very challenging. One of the most important factors to consider is device price. Pricing strategies that worked in the United States will not work in other geographies, and as a result, developing geography-specific pricing strategies is essential to avoiding commercial failure.

To be successful, you will need to understand the dynamics driving the global pricing environment, one where a multitude of factors drive vastly different price points and one where unique factors combine to drive very different pricing growth patterns.

While the United States will remain the largest and one of the highest-priced markets in the global medical device marketplace, the rest of the world offers numerous opportunities. Understanding the current state of global pricing and what to expect in terms of price and growth will allow manufacturers to plan where to best focus their efforts and what to expect in terms of success.

Related Market Assessment Reports

Report
Pulmonary Hypertension – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Pulmonary hypertension (PH) is a high-burden condition with significant unmet needs across the major markets. Despite its small patient pool, the commercial potential for PH therapies is…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Reduced Ejection Fraction (US)
Heart failure with reduced ejection fraction (HFrEF) occurs when the left ventricular ejection fraction (LVEF) is 40% or less. Drug treatment for HFrEF is well established and supported by…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Heart Failure with Preserved Ejection Fraction (US)
Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricular ejection fraction (LVEF) is 50% or more. Even though physicians’ understanding of the disease’s…
Report
Hypertension – Unmet Need – Unmet Need – Resistant Hypertension (US/EU)
Resistant hypertension (RHTN) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with…
Report
Heart Failure – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Heart Failure (US)
Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…